The effect of ACTH4-9 analog (Org2766) on some cerebrospinal fluid parameters in patients with Alzheimer's disease.
In a double-blind, placebo-controlled study, the central nervous system effects of an ACTH4-9 analog, Org2766 (40 mg/day), in Alzheimer's disease were assessed by measuring cerebrospinal fluid parameters during 6 months' treatment. Somatostatin-like immunoreactivity and cholinesterase activity, which are known to be reduced in cerebrospinal fluid of Alzheimer patients compared with controls, did not change during treatment. As a marker of noradrenergic and dopaminergic systems, we measured dopamine-beta-hydroxylase and homovanillic acid, but both levels were static. These results suggest that Org2766 did not interact with the transmitter systems, which are thought to be disturbed in Alzheimer's disease.
Jolkkonen
J T
JT
Soininen
H S
HS
Riekkinen
P J
PJ
D000324:Adrenocorticotropic Hormone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000368:Aged; D000544:Alzheimer Disease / Q000134:cerebrospinal fluid* / Q000188:drug therapy; D002802:Cholinesterases / Q000134:cerebrospinal fluid; D000242:Cyclic AMP / Q000134:cerebrospinal fluid; D004299:Dopamine beta-Hydroxylase / Q000134:cerebrospinal fluid; D004311:Double-Blind Method; D005260:Female; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006801:Humans; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000627:therapeutic use*; D010455:Peptides / Q000134:cerebrospinal fluid
D010446:Peptide Fragments; D010455:Peptides; C029993:somatostatin-like peptides; C013765:Org 2766; D000324:Adrenocorticotropic Hormone; D000242:Cyclic AMP; D004299:Dopamine beta-Hydroxylase; D002802:Cholinesterases; D006719:Homovanillic Acid